Skip to main content

Table 2 Comparison of the main characteristics of HIV infected-men enrolled in the study according to their CD4+ cells count at the time of cART initiation

From: Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients

  Blood CD4+ T count at the time of diagnosis (cells/mm3) p value
>350 “high-level CD4 group” (n = 9) <350 “low-level CD4 group” (n = 15)
At the time of diagnosis
 Route of contamination (%)
  MSM or bisexual 100 86.7 0.51
  Heterosexual 0 13.3 0.51
 Stage CDC of HIV infection (%)
  A (PHI) 62.5 6.7 0.01
  B or C 0 40 0.05
At the time of blood and biopsy sampling
 Age, median in years [range] 48 [28.5–49.5] 53 [46–61] 0.03
 Time since diagnosis of HIV infection, median in months [range] 40 [27.5–105.5] 44 [26–48] 0.63
 Total time on cART, median in months [range] 34 [18.5–60] 42 [24–46] 0.68
 cART regimen (%)
  3 NRTI 100 93.3 0.009
  2 NRTI/1 NNRTI 55.5 53.3 1
  2 NRTI/1 PI 44.4 46.6 1
  2 NRTI/1 II 0 13.3 0.51
At the time of cART initiation
 Time since diagnosis of HIV infection, median in months [range] 2 [0.5–73.5] 0 [0–1] 0.05
 Initiation at PHI stage (%) 33.3 6.7 0.13
 CD4+ T cells/mm3, median [range] 450 [427–695] 98 [31–257] <0.0001
 PVL in log10 copies/ml, median [range] 4.97 [4.24–6.1] 5.52 [5.17–5.94] 0.25
  1. cART combined antiretroviral therapy, CDC centers for disease control and prevention, II integrase inhibitors, PHI primary HIV infection, PVL plasmatic viral load, NNRTI non-nucleoside reverse transcriptase inhibitors, NRTI nucleoside reverse transcriptase inhibitors, PI protease inhibitors